You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Sparse-readout Quantitative PET scanner for breast cancer therapy optimization
SBC: PET/X LLC Topic: 102The goal of this project is to develop a quantitative molecular breast imaging PET QMBI PET scanner to improve the way in which breast cancer therapies are matched to individual patients by providing evaluation of therapy efficacy during the window of opportunity between diagnosis and surgical resection More than women in the US with invasive disease start therapy for breast cancer each ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Optimization of Pre- and Post-Operative Pain Management
SBC: CHANGE MANAGEMENT CONSULTING, LLC Topic: NIDAAbstract Despite joint replacement surgeries becoming an increasingly common surgical procedure uncontrolled post operative pain is a major cause of patient suffering and dissatisfaction and leads to chronic pain Development of chronic post surgical pain often treated with opioids is frequent and recognized as a major clinical problem Persistent opioid use due to uncontrolled chronic pain is ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis
SBC: Sanguine Diagnostics And Therapeutics, Inc. Topic: 103ABSTRACT Pancreatic cancer PC is an extremely aggressive malignancy with one of the worst prognoses of all cancers with a median survival of less than one year and an overall year survival of andlt With marked resistance to chemo and radiotherapies surgery is the only curative option In patients with localized disease and no lymph node or extra pancreatic metastases complete surgical ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Controlled Release Polymer Structures for In Situ Chemical Oxidation of Contaminated Groundwater
SBC: AXNANO LLC Topic: NIEHSDESCRIPTION provided by applicant The EPA estimates that one out of every four Americans lives within three miles of a hazardous waste site Over brownfield sites are awaiting remediation and sites on the National Priorities List Potential Responsible Parties or the Superfund program are tasked with remediating these sites but insufficient funding and growing number of sites hav ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Optimization of a novel cancer immunotherapeutic antibody for human use
SBC: CANCURE LLC Topic: 102ABSTRACT The goal of this application is to evaluate the cancer therapeutic feasibility of CanCureandapos s humanized first in class immunostimulatory monoclonal antibody mAb huB G the Product also names CuraB During cancer development in response to oncogenic insult or stress almost ALL human cancer cells are induced to express a SURFACE molecule MIC MHC I chain related Molecule wh ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Wireless sensor and telemedicine to screen for sleep apnea in elderly adults
SBC: ZANSORS LLC Topic: NIMHDABSTRACT Obstructive sleep apnea OSA is the most common type of sleep apnea OSA affects an estimated million adults and of all children in the US OSA results in tiredness depression and fatigue and has several associated common comorbidities It is believed that over of OSA remains undiagnosed The prevalence of OSA increases with age and if untreated increases the risk of ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of Chol-DsiRNA Polyplexes to Improve the Therapy of Breast Cancer
SBC: ACTORIUS PHARMACEUTICALS, LLC Topic: 100DESCRIPTION provided by applicant Breast cancer is the most common type of cancer in women between the ages of and and responsible for deaths annually If treated early five year survival rates for patients in the U S are between and but drop to once metastatic breast cancer has developed Thus there is a great need to develop more effective treatment strategies fo ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel Assay System and Analysis Algorithm in Detecting RNA Editing Events and Linked Splicing Isoforms
SBC: Celetrix LLC Topic: NIDAAbstract RNA editing is a process in which the genome encoded information is altered in RNA RNA editing is an efficient way to increase RNA complexity thereby fine tuning both gene function and dosage Adenosine to Inosine A to I editing is the most common type of RNA editing known in animals The cellular machinery recognizes inosine as guanosine so A to I editing of codons and splicing sign ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists
SBC: Bohemica Pharmaceuticals, LLC Topic: 100DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Potential of the Potassium Channel Inhibitor SHK-186 for Pediatric Lupus
SBC: KINETA, INC. Topic: RDESCRIPTION provided by applicant Systemic lupus erythematosus SLE is a chronic multisystem autoimmune disease with poorly understood etiology and pathogenesis and for which adequate treatment options are limited Although dysregulated production of autoantibodies and immune complex deposition are considered hallmarks of SLE considerable evidence supports the hypothesis that auto reactive ly ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health